Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BC-819 (DTA-H19) in Advanced Ovarian Cancer
NCT00826150Phase 2Completed
- Sponsor
- Anchiano Therapeutics Ltd.
- Start
- Jun 2009
- Primary completion
- Feb 2012
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of inodiftagene vixteplasmid in ovarian cancer, primary peritoneal carcinoma (PPC), sponsored by Anchiano Therapeutics Ltd.. Started Jun 2009; status: completed.
02
Drugs
inodiftagene vixteplasmid
03
Conditions
ovarian cancerprimary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT00826150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00826150.